Pharmacokinetics of dipyridamole-beta-cyclodextrin complex in dogs.
Plasma concentrations and urinary and fecal excretion of intact dipyridamole were followed in dogs after oral administration of dipyridamole-beta-cyclodextrin complex (dip-beta-CD) (capsules containing 37.5 and 75 mg of active principle), of commercial dipyridamole and of dipyridamole. HCl (tablets and capsules of 75 mg of active principle, respectively), according to a crossover design. Dip-beta-CD afforded significantly shorter lag-times, higher Cmax, smaller interindividual variations of plasma concentrations and greater urinary excretion than the other two preparations, as a consequence of a better bioavailability of the former one. This amelioration seems to be due not only to an increased wettability and water solubility of the product, but also to a finer molecular dispersion in the gastrointestinal fluids which favors the contact of dipyridamole with a greater absorption surface.
Stracciari
G L
GL
Institute of Pharmacology, Pharmacokinetics and Toxicology, Faculty of Veterinary Medicine, University of Bologna, Italy.
Malvisi
J
J
Anfossi
P
P
Fregnan
G B
GB
D000284:Administration, Oral; D000818:Animals; D001682:Biological Availability; D003505:Cyclodextrins / Q000008:administration & dosage / Q000493:pharmacokinetics*; D003912:Dextrins / Q000493:pharmacokinetics*; D004176:Dipyridamole / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics* / Q000652:urine; D004285:Dogs; D004338:Drug Combinations; D005243:Feces / Q000032:analysis; D005260:Female; D008297:Male; D013213:Starch / Q000493:pharmacokinetics*; D047392:beta-Cyclodextrins
D003505:Cyclodextrins; D003912:Dextrins; D004338:Drug Combinations; D047392:beta-Cyclodextrins; D004176:Dipyridamole; D013213:Starch; C031215:betadex